Reduction of etoposide induced cell killing by hyperthermia can occur without changes in etoposide transport or DNA topoisomerase II activity

International Journal of Hyperthermia

Volumn 12, Issue 4, 1996, Pages 551-567

  Ng, C E ^a   Bussey, A M ^a   Raaphorst, G P ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Drug transport; Etoposide; Hyperthermia; Topoisomerase activity

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

ARTICLE; CATALYSIS; CELL KILLING; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DRUG TRANSPORT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPERTHERMIC THERAPY; MELANOMA CELL;

EID: 0029745616     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.3109/02656739609023531     Document Type: Article

References (60)

1. ARMOUR, E. P., MCEACHERN, D., WANG, Z., CORRY, P., and MARTINEZ, A., 1993, Sensitivity of human cells to mild hyperthermia. Cancer Research, 53, 2740-2744.
2. BARLOGIE, B., CORRY, P. M., and DREWINKO, B., 1980, In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammine platinum (II) and mitomycin C. Cancer Research, 40, 1165-1168.
3. BERRIOS, M., OSHEROFF, N., and FISHER, P. A., 1985, In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophilia nuclear matrix fraction. Proceedings of the National Academy of Sciences, USA, 82, 4142-4146.
4. BICHAY, T. J., FEELEY, M. M., and RAAPHORST, G. P., 1992, A comparison of heat sensitivity, radiosensitivity and PLDR in four human melanoma cell lines. Melanoma Research, 2, 63-69.
5. BRILL, S. J., DINARDO, S., VOELKEL-MEINAN, K., and STERNGLANZ, R., 1987, Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature, 326, 414-416.
6. CHEN, M., and BECK, W. T., 1993, Teniposide-resistant CEM cells, which express mutant DNA topoisomerase IIα, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Research, 53, 5946-5953.
7. DE JONG, S., KOOISTRA, A. J., DE VRIES, E. G. E., MULDER, N. H., and et al., 1993, Topoisomerase II as a target of VM-26 and 4′-(9-acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Research, 53, 1064-1071.
8. DEWHIRST, M., 1994, Future directions in hyperthermic biology. International Journal of Hyperthermia, 10, 339-345.
9. DINARDO, S., VOELKEL, K., and STERNOLANZ, R., 1984, DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication. Proceedings of the National Academy of Sciences, USA, 81, 2616-2620.
10. DYNLACHT, J. R., WONG, R. S. L., ALBRIGHT, N., and DEWEY, W. C., 1994, Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase H-DNA cleavable complexes. Cancer Research, 54, 4129-4137.
11. EARNSHAW, W. C., HALLIGAN, B., COOKE, C. A., and HECK, M. M., Toposisomerase II is a structural component of mitotic chromosome scaffolds. Journal of Cell Biology, 100, 1706-1715.
12. EPPELBAUM, R., TEICHER, B. A., HOLDEN, S. A., ARA, G., VARSHNEY, A., and HERMAN, T. S., 1992, Interaction of D, L-and D-tetraplatin with hyperthermia in vitro and in vivo. European Journal of Cancer, 28, 794-800.
13. FISHER, G., and HAHN, G. M., 1982, Enhancement of cis-platinum (II) diamminechloride cytotoxicity by hyperthermia, National Cancer Inst. Monographs, 61, 255-257.
14. GASSER, S. M., and LAEMMLI, U. K., 1986, Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. Melanogaster. Cell, 46, 521-530.
15. GIOCANTI, N., HENNEQUIN, C., BALOSSO, J., MAHLER, M., and et al. 1993, DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Research, 53, 2105-2111.
16. GOSWAMI, P. C., HILL, M., HIGASHIKUBO, R., WRIGHT, W. D., and ROTI ROTI, J. L., 1992, The suppression of the synthesis of a nuclear protein in cells blocked in G2 phase: identification of NP-170 as topoisomerase II. Radiation Research, 132, 162-167.
17. HAHN, G. M., BRAUN, J., and HAR-KEDAR, I., 1975, Thermochemotherapy: synergism between hyperthermia (42-43°C) and adriamycin (or bleomycin) in mammalian cell inactivation. Proceedings National Academy of Sciences, USA, 72, 937-940.
18. HAHN, G. M., and LI, G. C., 1982, Interactions of hyperthermia and drugs: treatments and probes. National Cancer Institute of Monographs, 61, 317-323.
19. HALL, E. J., 1994, Radiobiology for the Radiologist, Ed. 4 (Lippencott Co.).
20. HECK, M. M. S., HITTELMAN, W. N., and EARNSHAW, W. C., 1988, Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. PNAS, USA, 85, 1086-1090.
21. HERMAN, T. S., 1983, Temperature dependence of adriamycin, cis-diammine-dichloroplatinum, bleomycin and BCNU in vitro. Cancer Research, 43, 517-520.
22. HOCHHAUSER, D., and HARRIS, A. L., 1993, The laboratory-clinic interface. The role of topoisomerase II α and β in drug resistance. Cancer Treatment Reviews, 19, 181-194.
23. HSIANG, Y., and LIU, L. F., 1988, Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug campthothecin. Cancer Research, 48, 1722-1726.
24. KALWINSKY, D. K., LOOK, A. T., DUNCORE, J., and FRIDLAND, A., 1983, Effects of epipodophyllotoxin VP16-213 on cell cycle traverse, DNA synthesis and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Research, 43, 1592-1597.
25. KAMPINGA, H. H., VAN DEN KRICK, G., and KONINGS, A. W., 1989, Reduced DNA break formation and cytotoxicity of the toposomerase II drug 4-(9′-acridinylamino) methane-sulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Cancer Research, 49, 1712-1717.
26. KAMPINGA, H. H., 1995, Hyperthermia, thermotolerance and topoisomerase II inhibitors. British Journal of Cancer, 72, 333-338.
27. KROLL, D. J., BORGERT, C. J., WEIDMANN, T. W., and ROWE, T. C., 1990, Drug sensitivity of heat-resistant mouse B16 melanoma variants. Radiation Research, 124, 15-21.
28. KUBOTA, N., KETEHI, M., and INADA, T., 1993, Hyperthermic enhancement of cell killing by five platinum complexes in human melanoma cells grown as monolayer cultures and multicellular spheroids. International Journal of Radiation Oncology Biology and Physics, 25, 491-497.
29. LEPOCK, J., 1982, Involvement of membranes in cellular responses to hyperthermia. Radiation Research, 92, 433-438.
30. LIU, L. F., 1989, Topoisomerase poisons as antitumor drugs. Annual Reviews in Biochemistry, 58, 351-375.
31. LORICO, A., RAPPA, G., and SARTORELLI, A. C., 1992, Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells. International Journal of Cancer, 52, 903-909.
32. MACKEY, M. A., ANOLIK, S. L., and ROTI ROTI, J. L., 1992, Cellular mechanisms associated with the lack of chronic thermotolerance expression in Hela S3 cells. Cancer Research, 52, 1101-1106.
33. MACKEY, M. A., and DEWEY, W. C., 1989, Cell cycle progression during chronic hyperthermia in S phase CHO cells. International Journal of Hyperthermia, 5, 405-413.
34. MATSUO, K., KOHNO, K., SATAO, S., UCHIUMI, K. T., TANIMURA, H., YAMADA, Y., and KUWANO, M., 1993, Enhanced expression of DNA topoisomerase II gene in response to heat shock stress in human epidermoid cancer KB cells. Cancer Research, 53, 1085-1090.
35. MIRSKI, S. E. L., EVANS, C. D., ALMQUIST, K. C., SLOVAK, M. L., and COLE S. P. C., 1993, Altered topoisomerase IIα in a drug resistant small cell lung cancer line selected in VP16. Cancer Research, 53, 4866-4873.
36. MUSK, S. R. R., and STEEL, G. G., 1990, The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. British Journal of Cancer, 62, 364-367.
37. NG, C. E., BUSSEY, A. M., and RAAPHORST, G. P., 1994, Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. International Journal of Radiation Biology, 66, 49-57.
38. NG, C. E., BUSSEY, A. M., MACDONALD, H. A., HELLER, D. P., WILKINS, D. E., and RAAPHORST, G. P., 1995, Cross sensitivity to x-radiation and type I and II DNA topoisomerase inhibitors in a range of human and rodent cell lines. International Journal of Oncology, 7, 1179-1184.
39. NG C. E., BUSSEY, A. M., and RAAPHORST, G. P., 1996, Sequence of treatment is important in the modification of camptothecin induced cell killing by hyperthermia. International Journal Hyperthermia, 12.
40. POMMIER, Y., 1993, DNA topoisomase I and II in cancer chemotherapy: update and perspectives. Cancer chemotherapy and Pharmacology, 32, 103-108.
41. POMMIER, Y., LETEUTRE, F., FESEN, M. R., FUJIMORI, A., BERTRAND, R., SOLARY, E. and et al., 1994, Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Investigations, 12, 530-542.
42. RAAPHORST, G. P., FEELEY, M. M., CHU, G. L., and DEWEY, W. C., 1993, A comparison of the effect of hyperthermia on DNA polymerase in hamster and human glioma cells. International Journal of Hyperthermia. 9, 303-312.
43. RAPPA. G., LORICO, A., and SARTORELLI, A. C., 1993, Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumour cell lines by novobiocin. Cancer Research, 53, 5487-5493.
44. READ, R. A., FOX, M. H., and BEDFORD, J. S., 1984, The cell cycle dependence of thermotolerance II. CHO cells heated at 45·0°C. Radiation Research, 98, 491-505.
45. RITKE, M. K., ROBERTS, D., ALLAN, W. P., RAYMOND, J., and et al., 1994, Altered stability of etoposide-induced topoisomerase II DNA complexes in resistant human leukemia K562 cells. British Journal of Cancer, 69, 687-697
46. ROBERGE, M., THING, J., HAMAGUCHI, J., and BRADBURY, E. M., 1990, The topoisomerase II inhibitor VM-26 induced marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation and chromosome condensation in G2 and mitotic BHK cells. Journal of Cell Biology 111, 1753-1762.
47. SAPARETO, S. A., HOPWOOD, L. E., DEWEY, W. C., FAJU, M. R., and GRAY, J. W., 1978, Effect of hyperthermia on survival and progression of CHO cells. Cancer Research, 38, 393-400.
48. SCHNEIDER, E., HORTON, J. K., YANG, C. H., NAKAGAWA, M., and et al., 1994, Mulitdrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Research, 54, 152-158.
49. SLICHENMYER, W. J., ROWINSKY, E. K., DONEHOWER, R. C., and KAUFMAN, S. H., 1993, The current status of camptothecin analogues as antitumor agents. JNCI, 85, 271-291.
50. SMITH, P. J., ANDERSON, C. O., and WATSON, J. V., 1986, Predominant role for DNA damage in etoposide-induced cytotoxicity and cell cycle perturbation in human SV40-transformed fibroblasts. Cancer Research, 46, 5641-5445.
51. SULLIVAN, D. M., GLISSON, B. S., HODGES, P. K., SMALLWOOD-KENTZO, S., and ROSS, W. E., 1986, Proliferation dependence of topoisomerase II mediated drug action. Biochemistry, 25, 2248-2256.
52. TAKANO, H., KOHNO, K., ONO, M., UCHIDA, Y., and KUWANO, M., 1991, Increased phophorylation of DNA topisomerase II in etoposide resistant mutants of human cancer KB cells. Cancer Research, 51, 3951-3957.
53. TOFFOLI, G., BEVILACQUA, C., FRANCHECHIN, A., and BOIOCCHI, M., 1989, Effect of hyperthermia on intracellular drug accumulation and chemosensitivity in drug-sensitive and drug-resistant P388 leukemia cell lines. International Journal of Hyperthermia, 5, 163-172.
54. TRASK, D. K., DIDONATO, J. A., and MUELLER, M. T., 1984, Rapid detection and isolation and covalent DNA/protein complexes: application to topoisomerase I and II. EMBO, 3, 671-676.
55. UEMURA, T., OHKURA, H., ADACHI, Y., MORINO, K., SHIOZAKI, K., and YANAGIDA, M., 1987, DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell, 50, 917-925.
56. URANO, M., KAHN, J., and KENTON, L. A., 1988, Effect of bleomycin on murine tumor cells at elevated temperatures and two different pH values. Cancer Research, 48, 615-619.
57. WARTERS, R. L., and BARROWS, L. R., 1994, The heat sensitivity of HeLa S3 cell DNA topoisomerase II. Journal of Cell Physiology, 159, 468-474.
58. WARTERS, R. L., and BRIZGYS, L. M., 1988, Effects of topoisomerase II inhibitors on hyperthermic cytotoxicity. Cancer Research, 48, 3932-3938.
59. WOESNNER, R. D., MATTERN, M. R., MIRABELLI, C. K., JOHNSON, R. K., and DRAKE, F. H., 1991, Proliferation and cell-cycle dependent differences in expressions of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation, 2, 209-214.
60. YANG, C. J., HORTON, J. K., COWAN, K. H., and SCHNEIDER, E., 1995, Cross resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Research, 55, 4004-4009.